Highly Sensitive and Selective Anti-cancer Effect by Conjugated HA-Cisplatin in CD44 Overexpression Non-small Cell Lung Cancer

In spite of severe side effects, chemotherapy is widely used as a major anticancer treatment in non-small cell lung cancer (NSCLC). HA polymers have become a topic of interest for developing sustained drug delivery systems of peptide and protein drugs in subcutaneous formulations. Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anti-cancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties.